Kaidor (Citalopram Hydrochloride)

Citalopram blocks the serotonin transporter on presynaptic neurons, preventing reuptake of serotonin from the synaptic cleft. This raises extracellular serotonin levels, enhancing serotonergic signaling that is associated with mood regulation, anxiety control, and obsessive‑compulsive symptom relief.

The appropriate dose of Kaidor is determined by the prescribing clinician based on the patient’s condition, response, and tolerability. Dosage may start low and be titrated upward, but exact amounts should only be set by a qualified prescriber.

Safety data for citalopram in pregnancy and lactation are limited. Clinicians must weigh potential benefits against risks, and the drug should only be used if clearly needed. Women who are pregnant, planning pregnancy, or breastfeeding should discuss options with their healthcare provider.

To order Kaidor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Kaidor (citalopram) is a selective serotonin reuptake inhibitor, offering a relatively favorable side‑effect profile compared with some older antidepressants such as tricyclics. Compared with other SSRIs, citalopram is often chosen for its once‑daily dosing and lower drug‑interaction potential, though individual response varies.

Kaidor should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Kaidor is taken orally, usually as a tablet, with or without food. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their clinician, avoiding missed doses or abrupt discontinuation without medical advice.

Serious risks include the potential for serotonin syndrome when combined with other serotonergic agents, QT interval prolongation leading to cardiac arrhythmias, severe hyponatremia especially in the elderly, and emergent suicidal thoughts, particularly during early treatment or dose changes.

Kaidor is contraindicated in patients taking monoamine oxidase inhibitors, those with known hypersensitivity to citalopram or any component of the formulation, and individuals with a history of severe QT prolongation. Caution is also advised for patients with uncontrolled bipolar disorder or severe hepatic impairment.